Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and ... (nd Poland for Eastern and Central Europe...)

HOME >> MEDICINE >> NEWS

Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy

Date:6/1/2009

nd Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL, TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV], and ACTIQ(R) (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, clinical development of NUVIGIL, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industr
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
2. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
3. Cephalon Acquires Controlling Interest in Arana Therapeutics
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
6. Cephalon Quarterly Conference Call Invitation
7. Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
8. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
9. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon

Post Your Comments:

(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...

(Date:12/15/2009)... Dec. 15 Accelify is proud to announce ... of Advisors. David will serve as Director of Development ... Accelify,s National Board of Advisors. ,, David ... District,s Board of Education in June 1995. As the ... of over 600,000 stretching from Northeast Los Angeles through ...

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. ... globally or complete a product portfolio they also ... safety programs. ,, A new free, white paper ... a Hearing Conservation Program: US Airways ," details ... West led the newly formed company to enhance ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...

[0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs

... is an early or predisposing event in the pathogenesis ... research which appears online on September 23 in the ... Myelodysplastic syndrome is a heterogeneous group of diseases ... hematopoietic lineages, clonal evolution and a tendency to progress ...

... been used widely in the treatment of hypertension ... hypertension guidelines. Moreover, after myocardial infarction and in ... blockers prevents re-infarction, hospitalisation for heart failure, and ... that atenolol is not very effective in hypertension. ...

... of bleeding from solid abdominal organs has been traditionally ... which has latelybeen recognized as detrimental. // Although there ... hemorrhage, bleeding is still the direct cause of death ... ,There is a continuous search for the "magical drug" ...

... has produced two Anti-retrovirals which can be used ... Nevirapine and Zidovudine is produced by CMSI in ... two drugs were officially released by Sebastian Ouseperamppil, ... which could maintain the quality control and Research ...

... Reddy Union Minister of Information, Broadcasting and Culture, India ... public regarding the prevention and treatment of HIV infections. ... social relevance. The media could play an important role ... the different broadcasting tools such as radio, websites, SMS, ...

... study, published in the October issue of the journal ... immune system abnormalities, including reduced levels of NKT cells, ... cells in the liver regulate production of cytokines, which ... may contribute to obesity -related liver disease. ,The ...

Other Medicine News:Health News:Evidence against use of Beta blockers as first choice in the treatment of primary hypertension 2 Health News:Aprotinin in the treatment of hemorrhagic shock trauma patients 2 Health News:Obesity As A Contributor To Liver Disease 2

Chronic Exposure To Benzene May Result In Dysplasia Evidence against use of Beta blockers as first choice in the treatment of primary hypertension Aprotinin in the treatment of hemorrhagic shock trauma patients CMSI produces Low cost Anti-retroviral drugs in India Indian Minister wanted Media to Propaganda HIV/AIDS awareness Obesity As A Contributor To Liver Disease

(Date:12/15/2009)... Varian Medical Systems (NYSE: VAR ... first quarter of fiscal year 2010 following the close ... The news release will be followed by a teleconference ... The news release and a link to the ... website at: www.varian.com/investor . To access the ...

(Date:12/15/2009)... Dec. 15 Vivakor, Inc. (OTC ... divisions have reported strong performance in 2009. ... and development with divisional spokes developing multiple ... Product Pipeline strategy is anchored to the ... idea inception, Vivakor,s R&D efforts target commercialization ...

(Date:12/15/2009)... -- Estill Medical Technologies, Inc., a family-owned Texas company ... Fluid Infusion Warmer , a patented medical device being ... and emergency responders to lessen the effects ... Unit of South Lake Tahoe as the first-ever recipient ... ,, CALSTAR is a California-based nonprofit emergency ...

Breaking Medicine Technology:Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call 2 Vivakor Divisions Continue to Demonstrate Independent Growth 2 Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 2 Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 3 Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 4 Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 12882 1 Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 12882 2 American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients 3B Organizing Doctors to Oppose Government Run Hea 50645 1 American Society of Medical Doctors Established to Protect the Bond Between Physicians and Patients 3B Organizing Doctors to Oppose Government Run Hea 50645 2 News media registration open for 20th World Diabetes Congress 50640 1

[0] Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call [0] Vivakor Divisions Continue to Demonstrate Independent Growth [0] Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award

... IntertwinedROCHESTER, Minn., Feb. 4 Here are highlights from ... . You may cite this publication as often as ... attribution is required. Reprinting is allowed ... your editorial policies permit: Visit www.bookstore.mayoclinic.com or ...

... (OTCBB: ORMP.OB), a developer of alternative drug,delivery systems, ... of concept,study in South Africa of insulin suppositories, ... for two visits, with,two different formulations. , ... insulin absorption and reactive,glucose lowering effect. The suppositories ...

Other Medicine Technology:February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus 2 February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus 3 February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus 4 February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus 5 Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2

February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository

Joseph Double Hook 10 mm wide. Designated most popular model or size....

Exceptional comfort, handling and eye health with a convenient replacement schedule. Suitable for wearers seeking the ideal combination of convenience and performance in a planned replacement soft le...

The proven daily wear spherical soft contact lens....

Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...

Medicine Products:

Joseph Double Hook Frequency 55 Sphere Cibasoft Acuvue2

Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and ...(nd Poland for Eastern and Central Europe...),Health